Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma - Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Larocca, Alessandra (Università di Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza) ; Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona) ; Cavo, Michele (Seràgnoli Institute of Hematology. Bologna University School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Leleu, Xavier (CHU de Poitiers) ; Nadeem, Omar (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Hiemenz, John W. (Division of Hematology-Oncology. Department of Medicine. University of Florida) ; Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ; Touzeau, Cyrille (Université de Nantes) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Paner, Agne (Rush University Medical Center) ; Maisel, Christopher (Baylor Scott & White Charles A. Sammons Cancer Center) ; Mazumder, Amitabha (Oncology Institute of Hope and Innovation) ; Raptis, Anastasios (Universityof Pittsburgh School of Medicine) ; Moreb, Jan S. (Novant Health Hematology. Novant Health Forsyth Medical Center) ; Anderson, Kenneth C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Laubach, Jacob P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Thuresson, Sara (Oncopeptides AB) ; Thuresson, Marcus (Oncopeptides AB) ; Byrne, Catriona (Oncopeptides AB) ; Harmenberg, Johan (Oncopeptides AB) ; Bakker, Nicolaas A. (Oncopeptides AB) ; Mateos, M. V (Hospital Clínico Universitario (Salamanca))